Edwards Lifesciences Corporation: Strategic Acquisitions & Expansion into Heart Failure Management As A Key Growth Catalyst! 

In reviewing the latest results from Edwards Lifesciences, notable elements of growth and development paired with challenges shed light on the company’s financial and operational trajectory during the second quarter of 2024. With total company sales reaching $1.6 billion, this marked an 8% increase on a constant currency basis compared to the same period last year. While Transcatheter Aortic Valve Replacement (TAVR) growth was not as robust as expected, increasing by 6% globally, the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated impressive growth, with a 75% increase in sales.